Use of Erythromycin in Mustard-Induced Bronchiolitis

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis...

Date First Received: August 21, 2006

Last Updated: November 4, 2008

Verified by: Baqiyatallah Medical Sciences University, March 2006

Clinical Trial Phase: Phase 4 | Start Date: 

Overall Status: Completed

Brief Summary

Official Title: “Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans”

Intervention(s):

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Intervention(s) in this Clinical Trial

  • Drug: Erythromycin

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Documented chemical exposure
  • Clinical, spirometric and radiological findings were compatible with BO on High
  • Resolution Computed Tomography (HRCT)
  • Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria:

  • Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
  • History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
  • History of treatment with a systemic antibiotic within 7 days before the start of the study
  • Any investigational medicine within 4 weeks of the study
  • History of antibiotic injection within 6 weeks before the study
  • Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
  • Patients who were in the exacerbation phase of their respiratory complications
  • Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
  • Systemic antibiotics
  • Systemic Corticosteroids
  • Admission to the hospital
  • Abnormal kidney or liver function

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Clinical Trial Sponsor Information

Lead Sponsor: Baqiyatallah Medical Sciences University

Overall Clinical Trial Officials and Contacts

Mostafa Ghanei, Professor Study Director Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran  

Additional Information

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00367419

Study ID Number: S-340-14-6-1-PU-02

ClinicalTrials.gov Identifier: NCT00367419

Health Authority: Iran: Ethics Commission

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.